Premium
AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1
Author(s) -
Neelapu S.S.,
Locke F.L.,
Bartlett N.L.,
Lekakis L.J.,
Miklos D.,
Jacobson C.A.,
Braunschweig I.,
Oluwole O.,
Siddiqi T.,
Lin Y.,
Timmerman J.,
Reagan P.,
Navale L.,
Jiang Y.,
Aycock J.,
Elias M.,
Wiezorek J.,
Go W.Y.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_7
Subject(s) - medicine , refractory (planetary science) , clinical endpoint , oncology , gastroenterology , interim analysis , population , adverse effect , lymphoma , aggressive lymphoma , clinical trial , rituximab , physics , environmental health , astrobiology